CG Oncology (CGON) EBITDA (2023 - 2026)

CG Oncology (CGON) has 4 years of EBITDA data on file, last reported at -$66.4 million in Q1 2026.

• Quarterly EBITDA fell 57.3% year-over-year to -$66.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215.0 million (down 59.94% YoY) and the FY2025 annual result came in at -$190.8 million, down 66.37% from the prior year.
• EBITDA fell to -$66.4 million in Q1 2026, from -$48.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.7 million in Q1 2023 to a low of -$66.4 million in Q1 2026.
• A 4-year average of -$32.9 million and a median of -$28.3 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA tumbled 131.14% — and 2025, when it dropped 27.99%.
• Tracing CGON's EBITDA over 4 years: stood at -$19.4 million in 2023, then plunged by 96.58% to -$38.0 million in 2024, then dropped by 27.99% to -$48.7 million in 2025, then tumbled by 36.32% to -$66.4 million in 2026.
• The last three EBITDA figures came in at -$66.4 million (Q1 2026), -$48.7 million (Q4 2025), and -$51.1 million (Q3 2025), per Business Quant data.